Burzynski Research Institute, Inc.
Burzynski Research Institute, Inc.
Your view on BZYR
Overview
What the company does, where it operates, and who runs it.
About Burzynski Research Institute, Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Stanislaw R. Burzynski
- Headquarters
- 9432 Katy Freeway, Houston, TX, US
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Stanislaw R. Burzynski
- Headquarters
- 9432 Katy Freeway, Houston, TX, US
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to treat cancer. The company is also involved in the production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name.
It also offers consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Burzynski Research Institute, Inc., and the rating behind it. BZYR last traded at $0.03; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Burzynski Research Institute, Inc.. Starting points for Burzynski Research Institute, Inc.: EPS -$0.0076, beta 0.45 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Burzynski Research Institute, Inc.. Burzynski Research Institute, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Burzynski Research Institute, Inc.. Trailing twelve-month EPS for Burzynski Research Institute, Inc. stands at -$0.0076. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Burzynski Research Institute, Inc.. Burzynski Research Institute, Inc. has reported as a listed company since 1997. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Burzynski Research Institute, Inc. valued side by side against its closest peers. Burzynski Research Institute, Inc. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Burzynski Research Institute, Inc., and how their positions are changing. At a $3.4M market value, institutional positions materially move Burzynski Research Institute, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Burzynski Research Institute, Inc. executives and directors. Shares of Burzynski Research Institute, Inc. have traded between $0.02 and $0.06 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Burzynski Research Institute, Inc.. Burzynski Research Institute, Inc. is a $3.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Burzynski Research Institute, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Burzynski Research Institute, Inc.. Coverage tracks Burzynski Research Institute, Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.